Mass screening for neuroblastoma in infants in Japan: interim report of a mass screening study group
T Sawada, T Nakata, N Takasugi, K Maeda, Y Hanawa… - The Lancet, 1984 - Elsevier
T Sawada, T Nakata, N Takasugi, K Maeda, Y Hanawa, K Shimizu, M Hirayama, T Takeda…
The Lancet, 1984•ElsevierA mass screening system for the early detection by means of a vanillylmandelic acid test of
neuroblastoma in 6-month-old infants in Japan has been developed in eight districts. 16 of
the 281 939 infants screened by this test had neuroblastoma, equivalent to a very high
incidence of 1 in 17 621. 15 of the 16 children with neuroblastoma are alive; the other child
died 1 month after surgery. This mass screening system for neuroblastoma used in infancy
can help to improve prognosis in infants with this malignant disorder.
neuroblastoma in 6-month-old infants in Japan has been developed in eight districts. 16 of
the 281 939 infants screened by this test had neuroblastoma, equivalent to a very high
incidence of 1 in 17 621. 15 of the 16 children with neuroblastoma are alive; the other child
died 1 month after surgery. This mass screening system for neuroblastoma used in infancy
can help to improve prognosis in infants with this malignant disorder.
Abstract
A mass screening system for the early detection by means of a vanillylmandelic acid test of neuroblastoma in 6-month-old infants in Japan has been developed in eight districts. 16 of the 281 939 infants screened by this test had neuroblastoma, equivalent to a very high incidence of 1 in 17 621. 15 of the 16 children with neuroblastoma are alive; the other child died 1 month after surgery. This mass screening system for neuroblastoma used in infancy can help to improve prognosis in infants with this malignant disorder.
Elsevier